Basic Pharmacokinetics and Pharmacodynamic Principles
- 119 Downloads
The successful development of new molecules with utility in the prevention and treatment of cancer requires a thorough understanding of the pharmacologic properties of these agents. This includes characterizing their interactions with specific molecular targets and defining their pharmacokinetic and pharmacodynamic properties early in the clinical development process. Pharmacokinetics is the analysis of drug absorption, distribution, metabolism, and excretion.1 Often, a drug’s pharmacokinetic profile is summarized by a mathematical representation of its concentration in plasma over time. Understanding a drug’s pharmacokinetic properties is important both for the rational use of these new agents and for explaining the interpatient and intrapatient variability that occurs when these agents are administered to large populations of patients. Pharmacodynamics extends these observations by relating time-dependent kinetic processes to actual clinical drug effects including include both therapeutic and toxic drug actions. Therefore, pharmacodynamics is important because it is ultimately the discipline that relates drug pharmacokinetics to clinically relevant endpoints.
KeywordsCentral Compartment Mean Residence Time Elimination Rate Constant Chemoprevention Agent Drug Elimination
Unable to display preview. Download preview PDF.
- 1.Gilbaldi M. Introduction to Pharmacokinetics.In:Gilbaldi M, ed.Biopharmaceutics and Clinical Pharmacokinetics4th Edition ed. Philadelphia:Lea &Febiger; 1991:113.Google Scholar
- 4.Ratain MJ. Therapeutic relevance of pharmacokinetics and pharmacodynamics.Sem Oncol.1992;19:8–13.Google Scholar
- 8.Bourne DWA, Triggs EG, Eadie MJ.Pharmacokinetics for the non-mathematical.Lancaster: MTP Press Limited; 1986.Google Scholar
- 9.Theodore WH. Basic principles of clinical pharmacology.Clin Neuropharmacol.1990;8:1–13.Google Scholar
- 10.Collins JM. Pharmacokinetics and clinical monitoring. In: Chabner BA, Longo DL, eds.Cancer chemotherapy and biotherapy: Principles and practice.Second edition ed. Philadelphia: Lippincott-Raven; 1996.Google Scholar
- 11.Winter ME. Digoxin. In: Winter ME, ed.Basic clinical pharmacokinetics.Third edition ed. Vancouver: Applied Therapeutics, Inc.; 1994:198–235.Google Scholar
- 12.Bourne DWA.Mathematical modeling of pharmacokinetic data.Lancaster:Technomic Publishing Co.; 1995.Google Scholar
- 13.Gabrielsson J, Weiner D.Pharmacokinetic and pharmacodynamic data analysis concepts and applications.Second edition ed. Stockholm: Swedish Pharmaceutical Press; 1997.Google Scholar
- 14.Noe DA. Noncompartmental pharmacokinetic analysis. In: Grochow LB, Ames MM, eds.A clinician’s guide to chemotherapy: Pharmacokinetics and pharmacodynamics.Baltimore: Williams & Wilkins; 1998:515–530.Google Scholar
- 15.Sambol NC, Sechaud R. The population approach: Description and applications to anticancer agents. In: Grochow LB, Ames MM, eds.A clinician’s guide to chemotherapy: Pharmacokinetics and pharmacodynamics.Baltimore:Williams &Wilkins; 1998:531–549.Google Scholar